Affiliations 

  • 1 Department of Microbiology, West Bengal State University, Kolkata, West Bengal, India
  • 2 Department of Microbiology, Adamas University, Kolkata, West Bengal, India
  • 3 Department of Computational Biology and Biotechnology, Mahapurasha Srimanta Sankaradeva Viswavidyalaya, Guwahati, Assam, India
  • 4 Pharmacology Unit, Jeffrey Cheah School of Medicine and Health Sciences, Monash University, Bandar Sunway, Selangor Darul Ehsan, Malaysia
  • 5 Department of Rasa Shastra and Bhaishajya Kalpana, Institute of Medical Sciences, Faculty of Ayurveda, Banaras Hindu University, Varanasi, Uttar Pradesh, India
Drug Dev Res, 2023 Sep;84(6):1031-1036.
PMID: 37391892 DOI: 10.1002/ddr.22091

Abstract

Exosome-based targeted delivery of Proteolysis-Targeting Chimeras (PROTACs) is an innovative approach that provides a promising solution for addressing the complex issues of viral diseases. This strategy significantly mitigates the off-target effects associated with traditional therapeutics by facilitating targeted delivery of PROTACs, which in turn enhances the overall therapeutic outcomes. Challenges like poor pharmacokinetics and unintended side effects, commonly observed with conventional PROTACs usage, are effectively managed with this approach. Emerging evidence affirms the potential of this delivery mechanism in curbing viral replication. However, it is crucial to undertake more comprehensive investigations for optimizing exosome-based delivery systems and conducting stringent safety and efficacy assessments within preclinical and clinical settings. The advancements in this field could potentially redefine the therapeutic landscape for viral diseases, opening new vistas for their management and treatment.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.